Merck

4. Merck

Total Ad Spend: $285.5 million
Television: $133.7 million
Magazine: $87.8 million
Other: $64 million

After resolving the manufacturing and supply problems that constricted supplies of Zostavax for several years, Merck ($MRK) decided on a disease-awareness campaign to herald its revival in the market. The campaign must have worked, because Zostavax was one of the best-selling vaccines last year.


In the spotlight

Shingles awareness, $46.7 million
Nasonex, $46.3 million
Zostavax, $46 million


 

Merck
Read more on

Suggested Articles

Zejula
Pharma

GSK cancer unit, in 'building mode,' gets picky with M&A

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

by Carly Helfand
Novo Nordisk
Pharma

Novo's Ozempic scores major win with heart-helping FDA approval

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

by Kyle Blankenship
Bayer
Pharma

Bayer's 'tumor-agnostic' Vitrakvi rejected in England, Germany

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

by Eric Sagonowsky